Pearl Diagnostics
Diagnostic Tests & IVD · Health Care
$14.7Mtotal raised · 5 rounds on record
$11.2Mlatest round · Venture round · Mar 2026 · 7 mo ago
$3.8Mgrants · 3 grants · CORDIS
50+team · employees, estimated range
Overview
Pearl Diagnostics is changing the way clinicians diagnose lung infections. Our in vitro diagnostics identify circulating microbial extracellular vesicles.
Funding and backers
Total raised
$14.7M
5 rounds on record
Latest round
$11.2M
Venture round · Mar 2026 · 7 mo ago
Team
51-200
employees, estimated range
Grants
$3.8M
3 grants · CORDIS
The money's age
Fresh money
7 months since the last round · not hiring
Momentum
35/100
in the news, fresh money
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Oct 7
Certified Pearl Diagnostics Announces Publication of Clinical Studies Supporting FDA Clearance of MycoMEIA Aspergillus Assay · pearldx.com
Mar 19
Raised a round Venture round $11.2M · SEC Form D
Aug 6, 2025
Certified Pearl Diagnostics Announces FDA 510(k) Clearance for Groundbreaking MycoMEIA Aspergillus Urine Assay · pearldx.com
Jul 24, 2025
Won a grant $999k · CORDIS
Feb 23, 2022
Raised a round Venture round $3.5M · SEC Form D
2022
Founded
Mar 8, 2021
Won a grant $977k · CORDIS
Jul 18, 2017
Won a grant $1.8M · CORDIS
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Mar 2026 | $11.2M | — | SEC Form D |
| Grant | Jul 2025 | $999k | — | CORDIS |
| Venture round | Feb 2022 | $3.5M | — | SEC Form D |
| Grant | Mar 2021 | $977k | — | CORDIS |
| Grant | Jul 2017 | $1.8M | — | CORDIS |
Registers and programsofficial lists and records that name the company
| Legal entity | Pearl Diagnostics, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Kieren MarrExecutive Officer, DirectorSEC Form D
Eric GornsteinExecutive Officer, DirectorSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Loop Diagnostics is a biotech company that develops a diagnostic tool for sepsis, using an in vitro cellular immunoassay to detect it…
FirstLook Lung is a blood-based test that helps identify lung cancer risk before or alongside LDCT, for USPSTF-eligible adults. From DELFI…
Discover AliveDx, a leading in-vitro diagnostics company. Explore our blood bank reagents, Alba, and MosaiQ® solutions.
What we do. Our portable sensors detect pathogens, past and active viral infections, hormones, anddisease biomarkers in real-time.
Get innovative vaginal healthcare, powered by our state-of-the-art Vaginal Microbiome Test. Our clinical care platform includes Rx for…
Conan MedTech has pioneered a rapid Point-of-Care diagnostic device, utilizing a highly specific salivary biomarker to diagnose potential…
People
Kieren Marr
Executive Officer, Director
Eric Gornstein
Executive Officer, Director
Brad Spellberg
Director
John Cammack
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
News
Pearl Diagnostics Announces Publication of Clinical Studies Supporting FDA Clearance of MycoMEIA Aspergillus Assay
BALTIMORE, October 07, 2026--Pearl Diagnostics (PearlDX), a company pioneering a new generation of non-invasive tests for lung infections, today announced the publication of clinical studies supporting U.S. Food and Drug Administration (FDA) 510(k) cleara
Read more
Report
Pearl Diagnostics Announces Publication of Clinical Studies Supporting FDA Clearance of MycoMEIA Aspergillus Assay
- Clinical studies demonstrate MycoMEIA's performance as a non-invasive aid to diagnose invasive aspergillosis, with 92% sensitivity in a case-control study - - PearlDX to present clinical data on MycoMEIA at IDWeek 2026 on October 22 - BALTIMORE, October
Read more
Report
Pearl Diagnostics Announces FDA 510(k) Clearance for Groundbreaking MycoMEIA Aspergillus Urine Assay
BALTIMORE-(BUSINESS WIRE) 6 August 2025 11:00 AM - Pearl Diagnostics proudly announces that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the MycoMEIA Aspergillus Assay - the first urine-based assay to receive FDA clearance
Read more
Report
Pearl Diagnostics Announces FDA 510(k) Clearance for Groundbreaking MycoMEIA Aspergillus Urine Assay
BALTIMORE, August 06, 2025--Pearl Diagnostics proudly announces that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the MycoMEIA Aspergillus Assay - the first urine-based assay to receive FDA clearance as an aid to diagnose I
Read more
Report
Cystic Fibrosis Foundation Invests in Pearl Diagnostics to Advance Non-Invasive Detection of Pseudomonas and Aspergillus in Cystic Fibrosis
BALTIMORE - June 17, 2025 - Pearl Diagnostics, a Johns Hopkins University spin-off specializing in non-invasive diagnostics for lung infections, announced today it has received a strategic investment from the Cystic Fibrosis Foundation to support the deve
Read more
Report
Carb-X funds Pearl Diagnostics to assess detection of bacterial pneumonia via urine sample.
BOSTON - February 11, 2025 - Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) will award biotechnology company Pearl Diagnostics US$1M to develop a low-cost, low turnaround time urine assay for the detection of pneumonia caus
Read more
Report
Fatal Fungi Threaten Global Health, WHO Says
Pearl Diagnostics develops tests to diagnose the critical fungal infections the WHO highlighted on Tuesday. As we work with partners including GAFFI-The Global Action Fund for Fungal Infections and scientific collaborators around the world, we are advanci
Read more
Report
Pearl Diagnostics founder Dr. Kieren Marr's journey to retirement - then to CEO
Originally posted by Donte Kirby at Technical.ly Dr. Kieren Marr retired from a faculty position at Johns Hopkins University at the beginning of this year because she knew the impact...
Read more
Report
Baltimore startup raises $3.5M as it prepares to seek FDA approval for new pneumonia test
Originally posted by Matt Hooke at BizJournals A Baltimore medical company that aims to make it easier to diagnose a deadly type of pneumonia raised $3.5 million in an oversubscribed...
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Baltimore
United States
HQ
Contact Us
50-200 est. staff
1812 Ashland Avenue, Ste. G32, Baltimore, MD 21205